CRNX - Crinetics Pharmaceuticals Inc Stock Price, Fair Value and News

$30.68+0.77 (+2.57%)

Delayed as of 24 Jun 2025, 12:01 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CRNX Price Action

Last 7 days

-4.1%

Last 30 days

0.5%

Last 90 days

-14.7%

Trailing 12 Months

-34.4%

CRNX RSI Chart

CRNX Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

-8.54

Price/Sales (Trailing)

3.7K

Price/Free Cashflow

-10.56

CRNX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CRNX Fundamentals

CRNX Revenue

Revenue (TTM)

760.0K

Rev. Growth (Yr)

-43.59%

Rev. Growth (Qtr)

-100%

CRNX Earnings

Earnings (TTM)

-328.3M

Earnings Growth (Yr)

-44.59%

Earnings Growth (Qtr)

-20.07%

CRNX Profitability

Return on Equity

-26.18%

Return on Assets

-24.11%

Free Cashflow Yield

-9.47%

CRNX Investor Care

Shares Dilution (1Y)

18.79%

Diluted EPS (TTM)

-3.8

CRNX Alerts

1 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	760.0K	0	0	0
2024	2.0M	1.4M	1.0M	1.0M
2023	4.3M	4.8M	4.7M	4.0M
2022	2.0M	2.9M	3.8M	4.7M
2021	0	0	0	1.1M
2020	897.0K	897.0K	392.0K	735.0K
2019	2.4M	1.7M	1.7M	1.2M
2018	2.4M	2.3M	2.2M	2.4M
2017	953.0K	1.3M	1.7M	2.0M
2016	0	0	0	589.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.

CEO	Dr. R. Scott Struthers Ph.D.
WEBSITE	crinetics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	210

Crinetics Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Crinetics Pharmaceuticals Inc? What does CRNX stand for in stocks?

CRNX is the stock ticker symbol of Crinetics Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Crinetics Pharmaceuticals Inc (CRNX)?

As of Mon Jun 23 2025, market cap of Crinetics Pharmaceuticals Inc is 2.8 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRNX stock?

You can check CRNX's fair value in chart for subscribers.

Is Crinetics Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CRNX is over valued or under valued. Whether Crinetics Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Crinetics Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRNX.

What is Crinetics Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Jun 23 2025, CRNX's PE ratio (Price to Earnings) is -8.54 and Price to Sales (PS) ratio is 3.69 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRNX PE ratio will change depending on the future growth rate expectations of investors.